Orion Portfolio Solutions LLC Has $624,000 Stock Position in Masimo Co. (NASDAQ:MASI)

Orion Portfolio Solutions LLC lowered its stake in Masimo Co. (NASDAQ:MASI) by 10.3% during the third quarter, HoldingsChannel.com reports. The firm owned 4,681 shares of the medical equipment provider’s stock after selling 540 shares during the period. Orion Portfolio Solutions LLC’s holdings in Masimo were worth $624,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in MASI. NBC Securities Inc. increased its position in shares of Masimo by 47.1% in the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 73 shares in the last quarter. Fifth Third Bancorp increased its position in shares of Masimo by 16.4% in the 2nd quarter. Fifth Third Bancorp now owns 695 shares of the medical equipment provider’s stock valued at $88,000 after buying an additional 98 shares in the last quarter. Oak Thistle LLC increased its position in shares of Masimo by 5.2% in the 2nd quarter. Oak Thistle LLC now owns 2,079 shares of the medical equipment provider’s stock valued at $262,000 after buying an additional 103 shares in the last quarter. HHM Wealth Advisors LLC increased its position in shares of Masimo by 25.0% in the 2nd quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock valued at $79,000 after buying an additional 125 shares in the last quarter. Finally, Assetmark Inc. increased its position in shares of Masimo by 12.7% in the 3rd quarter. Assetmark Inc. now owns 1,183 shares of the medical equipment provider’s stock valued at $158,000 after buying an additional 133 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on MASI. Stifel Nicolaus restated a “buy” rating and issued a $190.00 price objective (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Wells Fargo & Company upped their price objective on shares of Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. Raymond James upgraded Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 target price for the company in a report on Wednesday, November 6th. Finally, BTIG Research increased their target price on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Masimo has an average rating of “Moderate Buy” and an average target price of $170.67.

Masimo Price Performance

Shares of NASDAQ MASI opened at $174.07 on Wednesday. The stock has a market capitalization of $9.32 billion, a price-to-earnings ratio of 121.37 and a beta of 1.01. The business has a 50-day moving average of $158.09 and a 200-day moving average of $133.59. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. Masimo Co. has a fifty-two week low of $101.61 and a fifty-two week high of $180.97.

Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.14. The company had revenue of $504.60 million during the quarter, compared to analysts’ expectations of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. Masimo’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.63 EPS. As a group, sell-side analysts predict that Masimo Co. will post 4.03 earnings per share for the current fiscal year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.